Antisense oligonucleotides in the treatment of lipid disorders: Pitfalls and promises

Netherlands Journal of Medicine

Volumn 71, Issue 3, 2013, Pages 118-122

  Besseling, J ^a   Hovingh, G K ^a   Stroes, E S G ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Antisense oligonucleotides; Lipid disorders; Mipomersen; PCSK9

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN C3; DIACYLGLYCEROL ACYLTRANSFERASE; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISIS 147764; ISIS 217376; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIPOMERSEN; NICOTINIC ACID; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; PROTEINASE INHIBITOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; LIPID; MESSENGER RNA;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CYTOPLASM; DRUG WITHDRAWAL; DYSLIPIDEMIA; ERYTHEMA; GENE MUTATION; HEART INFARCTION; HUMAN; INJECTION SITE REACTION; LIPID METABOLISM; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; GENETICS; RISK FACTOR;

CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; HUMANS; LIPIDS; OLIGONUCLEOTIDES, ANTISENSE; RISK FACTORS; RNA, MESSENGER;

EID: 84878288974     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-81.
2. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326:1423-7.
3. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. Cardiovasc Drugs Ther. 2005;19:403-14.
4. Huijgen R, Kindt I, Verhoeven SBJ, et al. Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterollowering treatment but a minority reaches treatment goal. PloS One. 2010;5:e9220.
5. Barter P. HDL-C: role as a risk modifier. Atherosclerosis (Supplements). 2011;12:267-70.
6. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. New Engl J Med. 2007;357:1301-10.
7. Chapman MJ, Redfern JS, McGovern ME, Giral P. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther. 2010;126:314-45.
8. Boden WE, Probstfield JL, Anderson T, et al. Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. New Engl J Med. 2011;365:2255-67.
9. HPS2-THRIVE Study of TREDAPTIVETM (Extended-Release Niacin/ Laropiprant) Did Not Achieve Primary Endpoint [Internet]. Merck. 2012 [cited 2013 Jan 10]. Available from: http://www. mercknewsroom.com/press-release/prescription-medicine-news/ merck-announces-hps2-thrive-study-tredaptive-extended-relea
10. Hooper AJ, Burnett JR. Dalcetrapib, a cholesteryl ester transfer protein modulator. Expert Opin Investig Drugs. 2012;21:1427-32.
11. Crooke RM. Antisense oligonucleotides as therapeutics for hyperlipidaemias. Expert Opin Biol Ther. 2005;5:907-17.
12. Crooke ST. An overview of progress in antisense therapeutics. Antisense Nucleic Acid Drug Dev. 1998;8:115-22.
13. Toth PP. Antisense therapy and emerging applications for the management of dyslipidemia. J Clin Lipidol. 2011;5:441-9.
14. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolaemia. In: Scriber C, Beaudet A, editors. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. 2001. p. 2863-913.
15. Sankatsing RR, Fouchier SW, De Haan S, et al. Hepatic and cardiovascular consequences of familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol. 2005;25:1979-84.
16. Visser ME, Witztum JL, Stroes ESG, Kastelein JJP. Antisense oligonucleotides for the treatment of dyslipidaemia. Eur Heart J. 2012;33:1451-8.
17. Akdim F, Tribble DL, Flaim JD, et al. Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia. Eur Heart J. 2011;32:2650-9.
18. Akdim F, Stroes ESG, Sijbrands EJG, et al. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J Am Coll Cardiol. 2010;55:1611-8.
19. McGowan MP, Tardif J-C, Ceska R, et al. Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy. PloS One. 2012;7:e49006.
20. Stein EA, Dufour R, Gagne C, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation. 2012;126:2283-92.
21. Visser ME, Akdim F, Tribble DL, et al. Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J Lipid Res. 2010;51:1057-62.
22. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:998-1006.
23. Mullick AE, Fu W, Graham MJ, et al. Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice. J Lipid Res. 2011;52:885-96.
24. Zaid A, Roubtsova A, Essalmani R, et al. Proprotein convertase subtilisin/ kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology (Baltimore, Md.). 2008;48:646-54.
25. Abifadel M, Rabès J-P, Devillers M, et al. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat. 2009;30:520-9.
26. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlle. Lancet. 2012;380:29-36.
27. Graham MJ, Lemonidis KM, Whipple CP, et al. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res. 2007;48:763-7.
28. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. New Engl J Med. 2009;361:2518-28.
29. Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med. 1989;226:271-6.
30. Merki E, Graham M, Taleb A, et al. Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice. J Am Coll Cardiol. 2011;57:1611-21.
31. Pollin TI, Damcott CM, Shen H, et al. A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection. Science. 2008;322:1702-6.
32. Yu XX, Murray SF, Pandey SK, et al. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. Hepatology (Baltimore, Md.). 2005;42:362-71.
33. Hovingh GK, De Groot E, Van der Steeg W, Boekholdt SM, Hutten B, Kuivenhoven JA, et al. Inherited disorders of HDL metabolism and atherosclerosis. Curr Opin Lipidol. 2005;16:139-45.
34. Soumian S, Albrecht C, Davies A, Gibbs R. ABCA1 and atherosclerosis. Vasc Med. 2005;10:109-20.
35. Rayner KJ, Esau CC, Hussain FN, et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature. 2011;478:404-7.